Home Multimedia Podcasts Drug Repositioning as a Viable Business Model Drug Repositioning as a Viable Business Model March 10, 2011 Aris Persidis, Ph.D., President, Biovista /wp-content/uploads/2018/09/gencast_030911.mp3 Business ethicDrugsEthicsEthics, law and policyPharmacology Also of Interest 10x Defends Patent Litigation Strategy after Criticism from Researchers, Rivals Alexandria Founder Talks Takeda, Massachusetts, NYC, and 30th Anniversary Lab Space Giant Alexandria Real Estate Navigates AI’s Impact on Biopharma 89bio’s MASH Drug Begins Phase III, Aiming to Stand Out in Growing Field With $86M Oversubscribed Public Offering, Absci Eyes 2025 IND for Lead Candidate StockWatch: Challengers Take Aim at Lilly, Novo Nordisk Related Media BIO CEO Rachel King Outlines Industry's Challenges on "Close to the Edge" Emerging Markets Collaborate to Succeed in Post-Pandemic World Book Review: The Exceptions Global Single-Use Network Support Assurance of Supply Resins Address Downstream Purification Concerns Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies Related Content 10x Defends Patent Litigation Strategy after Criticism from Researchers, Rivals Alexandria Founder Talks Takeda, Massachusetts, NYC, and 30th Anniversary Lab Space Giant Alexandria Real Estate Navigates AI’s Impact on Biopharma 89bio’s MASH Drug Begins Phase III, Aiming to Stand Out in Growing Field